Metabolomics approaches for early cancer diagnosis: a review
Ali Zineddine Boumehira1,2, Yasmine Fatima Akchiche2, Wissam Cherfi2, Oualid Talhi3, Reda Djidjik4,5, Daniel Joe Dailin6, Ting Ho7, Hesham Ali El Enshasy6,8*
1Ecole Nationale Supérieure Agronomique – ENSA, El Harrach, Algiers, Algeria
2University of Algiers, Faculty of Sciences, LVBRN, Algiers, Algeria
3Centre de Recherche Scientifique et Technique en Analyses Physico-Chimiques CRAPC, Bou-Ismail, Tipaza, Algeria
4University of Algiers, Faculty of Medicine, LVBRN, Algiers, Algeria
5Department of Immunology, Issaad Hassani Hospital, Beni Messous, Algiers, Algeria
6Institute of Bioproduct Development (IBD), Universiti Teknologi Malaysia (UTM), Johor, Malaysia
7Global Agro Innovation (HK) Limited, Hong Kong
8City of Scientific Research and Technology Applications, New Burg Al Arab, Alexandria, Egypt
Abstract
Cancer remains a major burden on global public health with high mortality rates worldwide. Current diagnosis can detect cancer in late stages when therapy options become limited. Early diagnosis is broadly recognized as the key to a better treatment to save lives. The metabolomics approach provides a better understanding of the different types of cancer. They offer promising and potential interventions in biomarkers discovery which eventually will be better suited for individualized medicine. It elucidates endpoint products for other omic processes while significantly improving the understanding of pathogenesis and mechanisms yet to be discovered. Metabolomics offers a less-invasive, cost-effective for predicting, screening, diagnosis, prognosis, and monitoring therapeutic responses of the disease. There are two methods to study the metabolism and metabolites: targeted and untargeted. The workflow of these approaches requires different analytical platforms, such as Nuclear Magnetic Resonance spectroscopy (NMR), Mass Spectrometry (MS), and different bioinformatic tools. This review provides a systematic summary of metabolomics methods in identifying metabolic biomarkers of cancers (colorectal, prostate, breast, bladder, pancreas, lung, and buccal cancers). In addition, the current review will try to shed light on DNA lesions as a potential metabolic biomarker for cancer.
Keywords: Cancer, Metabolomics, NMR, Early diagnosis, DNA lesions
